论文部分内容阅读
目的探讨行经皮冠状动脉介入治疗(PCI)术中冠脉内应用替罗非班对急性心肌梗死患者血清超敏C反应蛋白(hs-CRP)和可溶性CD40配体(sCD40L)的影响。方法行PCI手术的82例急性心肌梗死患者随机分为两组,对照组40例,治疗组42例;对照组采用常规治疗,治疗组在行PCI术中冠脉内注射替罗非班。观察PCI术后的血流,血清hs-CRP和sCD40L。结果梗死相关冠脉血流(TIMI)达到3级的对照组33例,治疗组40例,两组有统计学差异(P<0.05)。两组在治疗后均明显改善了患者血清hs-CRP和sCD40L,并且治疗组改善更加明显(P<0.05),具有统计学意义。结论 PCI术中冠脉内使用替罗非班可以明显改善急性心肌梗死患者的血流,减少血清hs-CRP和sCD40L的表达。
Objective To investigate the effect of percutaneous coronary intervention (PCI) on the serum levels of hs-CRP and soluble CD40 ligand (sCD40L) in patients with acute myocardial infarction. Methods 82 patients with acute myocardial infarction undergoing PCI were randomly divided into two groups: control group (n = 40) and treatment group (n = 42). Patients in the control group were treated with conventional therapy. Patients in the treatment group were given PCI with tirofiban. Blood flow after PCI, serum hs-CRP and sCD40L were observed. Results 33 cases of infarction-related coronary flow (TIMI) reached level 3 in control group and 40 cases in treatment group, with statistical significance (P <0.05). Serum hs-CRP and sCD40L were significantly improved in both groups after treatment, and the improvement in the treatment group was more obvious (P <0.05), with statistical significance. Conclusion Tirofiban at coronary artery can improve the blood flow and reduce the expression of hs-CRP and sCD40L in patients with acute myocardial infarction.